26 April 2013 | Company results | By BioSpectrum Bureau
Boehringer Ingelheim China has high hopes on its core products, Mucosolvan, Micardis, Spiriva, Sifrol and Actilyse
Singapore: Boehringer Ingelheim China's prescription medicine business has outperformed the market with a growth rate of 32 percent in 2012.
With core products including Mucosolvan ampoules for respiratory diseases, Micardis for hypertension, Spiriva for COPD, Sifrol for Parkinson's disease and Actilyse for lytic treatment for stroke, Boehringer Ingelheim aims to continue to achieve strong sales in prescription medicines in China.
"We see significant potential in China as one of the major strategic markets for the company's future growth," said Professor Andreas Barner, chairman of the board of managing directors. "We are committed to investing and to introducing more innovative medicines and animal health solutions in China."
"In addition to our existing comprehensive portfolio, we are actively introducing products with blockbuster status or blockbuster potential to China, aiming for leadership in key therapeutic areas including stroke prevention in atrial fibrillation, diabetes, oncology and hepatitis C," stated Mr Allan Hillgrove, member of the board of managing directors.